Explore how Life Sciences organizations can accelerate Real World Evidence (RWE) to achieve faster time to insight, in a comprehensive and cost efficient manner. Download this white paper to learn about challenges, solutions and most importantly — how to equip your organization for success.

A top 10 pharmaceutical company wanted to focus on enhancing field intelligence to get a better picture of the local landscape and key players. With advanced data and analytics they were able to see relationships between providers that weren’t evident before, allowing them to target teams versus individuals.

By recognizing key trends and patterns that allow patients to be diagnosed earlier and therapy to be initiated sooner, AI techniques are already delivering results for three stakeholder groups — life sciences companies, health insurers and diagnostic labs. For each group, the AI-derived insight has direct clinical, business and financial implications.

This white paper includes findings from the OPG Perspectives Summit convened by McCann Managed Markets at the American Medical Group Association (AMGA) Annual Conference, which included C-suite executives from 9 leading organized provider group (OPG) organizations. The white paper explores trends and market forces affecting OPGs and identifies opportunities for pharmaceutical manufacturers to partner with OPGs to develop mutually beneficial programs addressing areas of shared interest.

The pharmaceutical industry is responsible for the successful execution of hundreds of thousands of trials of new drugs and vaccines. Gene therapy trials are unique, combining established experience and new approaches previously unnecessary for developing new drugs.

This paper will focus on the challenges with collecting data required for a protocol and best practices to address them. Learn how to meet the demands of modern trials with modern, cloud based electronic data capture (EDC) systems that enable you to run the trial you want.

Virtually engaging Healthcare Professionals in a meaningful dialogue provides deeper engagements, opening up more possibilities for the delivery of brand and disease information for providers. Virtual pharmaceutical representatives, supported by state of the art technology are evolving the way pharmaceutical industry succeeds by seamlessly connecting brands to healthcare providers.

Emerging Pharma Leaders

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.